RECORD // Company

Zentalis Pharmaceuticals, Inc.

Formerly: Zentalis Pharmaceuticals, LLC; Zeno Pharma, LLC

Built 2026-11-21T11:37:26Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (2)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Zentalis Pharmaceuticals · Ctgov · exact name match to 'Zentalis Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • ZENTALIS PHARMACEUTICALS, INC. · Ny corps · same registered legal name as 'Zentalis Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001725160-26-000070

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-28,815,0003 months ended 2026-09-3010-Q2026-11-090001725160-26-0000702026-11-21 11:37 UTCReport an error
Cash and cash equivalents$24,029,000at 2026-09-3010-Q2026-11-090001725160-26-0000702026-11-21 11:37 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001725160
Ticker
ZNTL
EIN
823607803
CUSIP
98943L107
Record ID
sx:sec:0001725160

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
Business address10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 921212026-11-16SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:37 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-137,060,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:37 UTCReport an error
Total assets (at 2025-12-31)$288,967,0002025-12-3110-K, XBRL Assets2026-11-21 11:37 UTCReport an error
Stockholders' equity (at 2025-12-31)$216,204,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:37 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$35,995,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:37 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-125,247,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:37 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:37 UTCReport an error
Operating lease liabilities (at 2025-12-31)$39,577,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:37 UTCReport an error
Form D total offering amount (D filed 2019-09-05)Indefinite2019-09-05D2026-11-21 11:37 UTCReport an error
Form D total amount sold (D filed 2019-09-05)$02019-09-05D2026-11-21 11:37 UTCReport an error
Form D industry groupPharmaceuticals2019-09-05D2026-11-21 11:37 UTCReport an error
Form D revenue rangeDecline to Disclose2019-09-05D2026-11-21 11:37 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.2026-11-09SEC EDGAR 8-K 0001725160-26-000069 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-09)Beginning November 9, 2026, spokespersons of the Company plan to present the information in the Corporate Presentation furnished as Exhibit 99.2 to this Current Report and incorporated herein by reference at conferences and in meetings with investors and analysts. The information in Items 2.02 and 7.01 of this Current Report (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, whether…2026-11-09SEC EDGAR 8-K 0001725160-26-000069 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-14)On August 13, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering, issuance and sale by the Company of 23,000,000 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at an offering price of $3.50 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-286122) and a related prospectus…2026-08-14SEC EDGAR 8-K 0001628280-26-057112 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.2026-08-06SEC EDGAR 8-K 0001725160-26-000061 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-06)Beginning August 6, 2026, spokespersons of the Company plan to present the information in the Corporate Presentation furnished as Exhibit 99.2 to this Current Report and incorporated herein by reference at conferences and in meetings with investors and analysts. The information in Items 2.02 and 7.01 of this Current Report (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, whether…2026-08-06SEC EDGAR 8-K 0001725160-26-000061 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
Plan (welfare, plan no. 501)ZENTALIS PHARMACEUTICALS HEALTH & WELFARE PLAN: 119 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:37 UTCReport an error
Largest institutional holder #1 (13F as filed): 5AM Venture Management, LLC$19,147,3782026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$18,204,5972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #3 (13F as filed): Squadron Capital Management LLC$17,945,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #4 (13F as filed): TWO SIGMA INVESTMENTS, LP$14,670,9402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$13,752,9952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #6 (13F as filed): CITADEL ADVISORS LLC$11,147,2542026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #7 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$7,804,0282026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #8 (13F as filed): Opaleye Management Inc.$6,851,3822026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #9 (13F as filed): ORBIMED ADVISORS LLC$6,744,2942026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #10 (13F as filed): Decheng Capital LLC$6,418,1362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.